Indian Pharmaceutical Stocks Opened In Deep Red Today, with the Nifty Pharma Index Falling 1.82 per cent to 21,576.85 points as markets reacted to Us President Donald Trump’s Announcement of a 100 per cent import tarif On Branded Pharmaceutical Products, Effective October 1, 2025.
The sector witnessed broad-based selling with 19 out of 20 stocks declining. Sun Pharma Led the losers, Dropping 2.76 per cent to ₹ 1,582.50, While Biocon Fell 3.24 per cent to ₹ 344.40. Natco Pharma was the Worst Performer, Declining 3.51 per cent to ₹ 812.75. Only IPCA Labs Managed to Stay in Positive Territory with a Marginal 0.10 per cent gain.
Choice Institutional Equites Analyst Maitri Sheth Warned That The Tariff Could Negative Cent of the expenses valued at $ 10 billion in FY25. “While the tariff primarily targets branded drugs, there is Ambiguity Over Whether Complex Generics and Specialty Medicines Might ALSO BE Affeted,” SHETH noted.
The tariff Announcement Includes Examptions for Companies that have Alredy Begun Construction on Us Manufacturing Facilites or have such facilityes Under Development. This provides some reliable for firms with existing american operations, thought the broader sector remain vulnerable to the policy change that AIMS to Boost Domestic Us Manufacturing and Reduce Implant Deependence.
More like this
Published on September 26, 2025